Transdermal drug delivery systems offer a promising alternative to conventional administration routes by enabling non-invasive, controlled, and sustained drug release. Granisetron hydrochloride, used primarily to prevent chemotherapy-induced nausea and vomiting, was extensively characterized for potential transdermal application. Physical characterization confirmed its crystalline nature, high melting point (301±1°C), and specific functional groups through FTIR and DSC analyses, indicating purity .Preformulation studies showed excellent solubility in water, phosphate buffer, methanol, and chloroform, while the partition coefficient indicated low lipophilicity. Compatibility studies revealed no significant interactions with excipients. A standard calibration curve in phosphate buffer saline (pH 7.4) was developed for quantitative analysis. Overall, Granisetron hydrochloride demonstrates potential for transdermal delivery, offering improved therapeutic outcomes for chemotherapy-induced nausea and vomiting.